openPR Logo
Press release

JAMA Psychiatry meta-analysis confirms deprexis efficacy

02-27-2017 03:33 PM CET | Health & Medicine

Press release from: GAIA AG

/ PR Agency: Crowdfluence Ltd
Jama Psychiatry meta-analysis confirms deprexis efficacy

Jama Psychiatry meta-analysis confirms deprexis efficacy

* Gaia AG’s self-guided internet-based cognitive behavioral therapy effective in treating depressive symptoms *

Hamburg, Germany: GAIA AG, a global pioneer in digital therapy, announced today that deprexis®, a web-based EC- and FDA-cleared medical device developed by GAIA, has once again been proven to be effective in a global scientific study.

A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis® for the treatment of depression. The software is one of GAIA’s developments. It has recently been licensed to Servier globally, except for the US and Japan. The meta-analysis was a truly global collaborative effort, as 26 researchers from the Netherlands, the US, UK, Australia, Germany, Switzerland, and Spain combined data from 13 randomized controlled trials with a total of 3876 study participants. Of the 13 trials, 5 had examined deprexis (38%), and 1199 of the participants came from deprexis studies (31%). There were no other interventions from Germany. The average effect size reported for deprexis studies was 0.53, compared to 0.28 for others.

“We are very pleased with the results of this meta-analysis. It confirms the results of previous randomized controlled trials (RCTs) on deprexis®,” added Mario Weiss, CEO and founder of GAIA. “Depression is a widely-spread pathology, with around 350 million people worldwide suffering from it (WHO). Patients benefit greatly from deprexis® as an adjunct therapy, in addition to pharmacologic or psychotherapeutic treatments.”

GAIA is a global leader in digital therapeutics. With its stringent focus on research and development of evidence based online interventions the company continuously shifts benchmarks when it comes to effect sizes and safety profiles for digital therapeutics in neuroscience. With more than 100 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering, as well as Regulatory and Market Access, GAIA is a key partner in the development of next generation digital solutions to support and treat patients with a broad variety of medical conditions.

More information: http://gaia-group.com/en

Crowdfluence Ltd (on behalf of Gaia AG)
1st Floor Healthaid House
Marlborough Hill
Harrow
Midxx HA1 1UD
UK
E-mail: suhela@crowdfluence.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release JAMA Psychiatry meta-analysis confirms deprexis efficacy here

News-ID: 450936 • Views:

More Releases from GAIA AG

Antidepressant digital therapy (deprexis®) effective in the US
03-03-2017 | Health & Medicine
GAIA AG
Antidepressant digital therapy (deprexis®) effective in the US
New trial confirms effectiveness of Gaia AG’s computer-based therapy deprexis with impressive effect size. Hamburg, Germany: GAIA AG, a global pioneer in digital therapy, announced today that deprexis®, a software developed by Gaia, has been demonstrated to be effective in a scientific study in the US. A randomized controlled trial (RCT) with N = 376 depressed adults, published in the latest issue of the Journal of Consulting and Clinical
Individual Online Help for Depression
07-30-2010 | Health & Medicine
GAIA AG
Individual Online Help for Depression
Depression is a common and growing disease. People who suffer from such a mental disease are often confronted with additional problems, both in their private and professional lives, as well as in their finances. Losing one’s job, friends and spending a lot of money for high-cost treatment like psychotherapy and medication at the same time add even more pressure to one’s already unhappy circumstances. And this is only the tip of

More Releases for Psychiatry

International Conference on Psychology and Psychiatry
Join leading psychologists, psychiatrists, researchers, and mental health professionals at the International Conference on Psychology and Psychiatry 2025 in Dubai! This premier event will feature cutting-edge research, insightful keynote sessions, interactive workshops, and global networking opportunities. Date: November 05-06, 2025 Venue: City Seasons Dubai Hotel, UAE Theme: Exploring the Frontiers of Psychology and Psychiatry Why Attend? Engage with world-renowned experts Discover the latest advancements in psychology and psychiatry Network with professionals from academia and industry Present
Personalized Psychiatry Market Top Companies Study - HMNC Holding GmbH, Arcara P …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Personalized Psychiatry Market- (By Type (Products, Services, Software), By Therapeutic Areas (Depression, Anxiety, Bipolar Disorder, Schizophrenia, Addiction, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Personalized Psychiatry Market is valued at US$ 4.2 Bn in 2023, and it is expected to reach
Personalized Psychiatry Market Top Players -
Personalized Psychiatry Market Worth $10.1 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Personalized Psychiatry Market- (By Type (Products, Services, Software), By Therapeutic Areas (Depression, Anxiety, Bipolar Disorder, Schizophrenia, Addiction, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Personalized Psychiatry
Personalized Psychiatry Market Top Players - GreyBird Ventures, Sunovion Pharmac …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Personalized Psychiatry Market- (By Type (Products, Services, Software), By Therapeutic Areas (Depression, Anxiety, Bipolar Disorder, Schizophrenia, Addiction, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Personalized Psychiatry Market is valued at US$ 4.2 Bn in 2023, and it is expected to reach
Personalized Psychiatry Market From Diagnosis to Recovery: Personalized Psychiat …
Global Personalized Psychiatry Market Worth $10.1 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Personalized Psychiatry Market- (By Type (Products, Services, Software), By Therapeutic Areas (Depression, Anxiety, Bipolar Disorder, Schizophrenia, Addiction, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Personalized
Personalized Psychiatry Market See Incredible Growth 2024-2031 | GreyBird Ventur …
New Research Study "Personalized Psychiatry Market 2024 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook" has been added to Coherent Market insight Personalized Psychiatry Market report provides a detailed analysis of global request size, indigenous and country- position request size, segmentation request growth, request share, competitive Landscape, deals analysis, impact of domestic and global request players, value chain optimization, trade regulations, recent developments,